Clinical Trial Update: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating QLF31907 for safety and efficacy in advanced melanoma and urothelial carcinoma is ongoing with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Urothelial Carcinoma

Drugs mentioned

• QLF31907

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Melanoma, Urothelial Carcinoma | Phase 2 | Status: UNKNOWN